Novel phenylboronic acid compounds and intermediates and processes for the preparation thereof

ABSTRACT

Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): 
     
       
         
         
             
             
         
       
         
         
           
             and also from the novel intermediates having the formulae (1), (2), (3) and (10):

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 11/454,859filed Jun. 19, 2006 and claims priority under 35 U.S.C. §119 of FR03/14946, filed Dec. 18, 2003, and is a continuation of PCT/FR2004/003192, filed Dec. 10, 2004 which designates the United States(published in the French language on Jul. 7, 2005 as WO 2005/061520 A1;the title and abstract were also published in English), each herebyexpressly incorporated by reference and each assigned to the assigneehereof.

SUMMARY OF THE INVENTION

The present invention relates to novel disubstituted derivatives ofphenylboronic acid, having the general formula (I):

in which:

R1 is a hydrogen atom or an alkyl radical having from 1 to 4 carbonatoms,

R2 and R3, which may be identical or different, are each an alkylradical having from 1 to 4 carbon atoms,

R4 is the —B(OH)₂ radical or the radical of formula:

to processes for the preparation thereof and to their use asintermediates in the synthesis of non-steroidal vitamin D derivatives.

Phenylboronic acid derivatives can be employed in Suzuki-type couplingreactions and are important intermediates in the synthesis ofnon-steroidal vitamin D3 analogues. Such reactions have been describedby the assignee hereof in WO 03/050067.

In WO 03/050067 the non-steroidal vitamin D derivatives of generalformula (IVa) (see FIG. 1) are obtained from intermediate triflates ofgeneral formula (5) and boronic acid intermediates of general formula(6).

The preparation of the intermediate triflates of general formula (5)involves 3 synthesis steps and that of the boronic acid intermediates ofgeneral formula (6) involves 6 synthesis steps.

In the present invention the synthesis of the phenylboronic acids ofgeneral formula (Ia) takes place in 4 steps and involves the use ofbromo derivatives of general formula (II) to obtain the non-steroidalvitamin D derivatives of general formula (IVa) according to FIG. 2. Thebromo derivatives of general formula (II) are prepared in 3 steps.

The use of the phenylboronic acids of general formula (I) of the presentinvention therefore exhibits as its first advantage access to thebiphenyl intermediates of general formula (III) in 7 steps in total (seeFIG. 2), whereas the synthesis described previously, in WO 03/050067,involves 9 steps for access to the biphenyl intermediates of generalformula (7) (FIG. 1).

The use of the phenylboronic acids of general formula (I) involves theutilization of bromo derivatives of general formula (II), which exhibitsas a second advantage the avoidance of the protection and deprotectionsteps required in order to prepare the boronic acid intermediates ofgeneral formula (6) that are used in the preceding synthesis (FIG. 1).Moreover, the protection step was carried out with methoxymethylchloride, a highly carcinogenic reactant which is prohibited on theindustrial scale.

A third advantage provided by the use of the phenylboronic acids ofgeneral formula (I) is that they allow access to the biphenylintermediates of general formula (III), in which the tertiary alcoholfunction is already present, whereas by proceeding via the biphenylintermediates of general formula (7) as described in WO 03/050067(FIG. 1) it is still necessary to convert the ketone function into atertiary alcohol function.

A fourth advantage provided by the use of the phenylboronic acids ofgeneral formula (I) is that they allow access to the non-steroidalvitamin D derivatives of general formula (IVa) in fewer steps than withthe synthesis as described in WO 03/050067 and with a better yield.

In the present invention novel phenylboronic acid derivatives have beensynthesized via a novel process, which allows the above problems to beremedied.

The present invention thus features novel disubstituted derivatives ofphenylboronic acid, having the general formula (I):

in which:

R1 is a hydrogen atom or an alkyl radical having from 1 to 4 carbonatoms,

R2 and R3, which may be identical or different, are each an alkylradical having from of 1 to 4 carbon atoms, and

R4 is the —B(OH)₂ radical or the radical of formula:

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1-4 illustrate a variety of reaction schemes for the ultimatepreparation of the compounds of formula (I).

DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED EMBODIMENTS OFTHE INVENTION

According to the present invention an alkyl radical having 1 to 4 carbonatoms is a saturated or unsaturated, linear or cyclic, optionallybranched radical which contains 1 to 4 carbon atoms and can beinterrupted by a heteroatom, and preferably the alkyl radicals having 1to 4 carbon atoms are methyl, ethyl, propyl, isopropyl, cyclopropyl,butyl, isobutyl or tert-butyl radicals.

The present invention also features the following novel intermediatecompounds:

Where, for compounds (2) and (3), R1 is a hydrogen atom or an alkylradical having from 1 to 4 carbon atoms, R2 and R3, which may beidentical or different, are each an alkyl radical having from 1 to 4carbon atoms and R₅ is an alkyl radical having from 1 to 4 carbon atoms.

The present invention likewise features employing the compounds (1), (2)and (3) for preparing non-steroidal vitamin D analogues and, inparticular, as synthesis intermediates for preparing compounds offormula (I) according to the invention.

This invention, therefore, also features a process for synthesizing thesubject novel phenylboronic acid derivatives of formula (I).

The synthesis of these novel phenylboronic acid compounds of generalformula (I) in which R4 is the B(OH)₂ radical is carried out in 4 stepsstarting from methyl 4-bromo-3-methylbenzoate (commercial product)according to the scheme of FIG. 3.

Therefore, the process for preparing compounds of general formula (I) inwhich R4 is the B(OH)₂ radical comprises the following steps, steps a)and b) not being implemented in the specific case in which R1 is ahydrogen atom:

a) bromination in the benzylic position in the presence of a solvent, togive the compound (1):

b) substitution of the bromine introduced in step a) in the benzylicposition by an alkyl chain R₅ containing 1 to 4 carbon atoms, to givethe compound (2) as defined above:

c) conversion of the ester function of the intermediates of generalformula (2) or of methyl 4-bromo-3-methylbenzoate into a tertiaryalcohol function, using at least two equivalents of an organomagnesiumcompound of formula R2-MgX

wherein X is a chlorine or bromine atom

and R2 is a methyl, ethyl, propyl or butyl radical, to give the compoundof general formula (3) as defined above:

d) conversion of the aromatic bromide of the intermediates of generalformula (3) into phenylboronic acid of formula (I) in the presence of asolvent, a base and a trialkyl borate.

In greater detail, the steps of this process may be carried out asfollows:

a. The first step entails performing a bromination in the benzylicposition to give the intermediate (1). This halogenation reaction isdescribed in the literature. Various brominating agents may be used,such as, for example, bromine (K. Smith et al., J. Chem. Soc. Perkin.Trans., I, 2000, 2745), N-bromosuccinimide (P. Liu et al., Synthesis,2001, 2078), sodium bromate (D. Kikuchi et al., J. Org. Chem., 1998,6023) or else 1,3-dibromo-5,5-dimethylhydantoin (H. Jendralla et al.,Liebigs Ann. Chem., 1995, 1253). This reaction is carried out most oftenin chlorinated solvents or in ethers. The brominating agent used withpreference is N-bromosuccinimide at dichloromethane reflux. Preferably,benzoyl peroxide is also used, in a catalytic amount, as a free-radicalreaction initiator. In order to activate the free-radical reaction thereaction mixture is irradiated with a 1000 watt lamp.

This step provides the intermediate (1):

b. The second step entails substituting the bromine introduced in step 1in the benzylic position by an alkyl chain R′1 containing 1 to 4 carbonatoms. In order to promote this substitution reaction the nucleophiliccharacter of the alkyl group R′1 is increased by using an organometallicreagent R′1-M in which M is a metal atom such as magnesium, copper orelse zinc. This reaction is described in the literature (B. H. Lipshutzand S. Sengupta, Organic Reactions, 1992, 41, 135). Preferably, copperin the form of copper iodide is employed in the presence of anorganomagnesium compound R′1-MgX (X═Br, CI, I) in order to generate anorganocuprate. This reaction may be carried out in ethereal solvents.Preferably the ethereal solvent used is tetrahydrofuran. The reaction iscarried out at low temperature, preferably from −40° C. and 0° C., moreparticularly from −40° C. and −20° C.

This step provides the intermediates of general formula (2), theradicals of which are defined above.

c. The third step entails converting the ester function of theintermediates of general formula (2) or of methyl4-bromo-3-methylbenzoate into a tertiary alcohol function, using atleast two equivalents of an organomagnesium compound of formula R2-MgX,wherein X is a chlorine, bromine or iodine atom and R2 is an alkylradical having 1 to 4 carbon atoms. This reaction is widely described inthe literature. This reaction may be carried out in ethereal solvents.Preferably, the ethereal solvent used is tetrahydrofuran. The reactionis preferably carried out at a temperature of from −20° C. and +20° C.,more particularly from −10° C. and +10° C.

This step provides the intermediates of general formula (3), theradicals of which are defined above.

d. The fourth step entails converting the aromatic bromide of theintermediates of general formula (3) into phenylboronic acid of formula(I). This reaction, which is well documented in the literature (N.Miyaura & A. Suzuki, Chem. Rev., 1995, 95, 2457), is carried out intetrahydrofuran at temperatures of from −78° C. and −20° C., preferablyfrom −78° C. and −40° C. From 2 and 4 equivalents of a strong base areused such as butyllithium, preferably from 2.5 and 3.5 equivalents, anda trialkyl borate is used, such as trimethyl borate or triisopropylborate. From 2 and 4 equivalents of the latter are used, preferably from2.5 and 3.5 equivalents.

According to another embodiment according to the invention, thesynthesis of these novel phenylboronic acid derivatives of generalformula (I) in which R4 is the radical of formula:

is carried out in 4 steps starting from methyl 4-bromo-3-methylbenzoate(commercial product) according to the scheme of FIG. 3.

The first three steps are similar to the process described above.

Therefore, the process for preparing compounds of general formula (I)

in which R4 is the

radical comprises the following steps, steps a) and b) not beingimplemented in the specific case in which R1 is a hydrogen atom:

a) bromination in the benzylic position in the presence of a solvent, togive the compound (1):

b) substitution of the bromine introduced in step a) in the benzylicposition by an alkyl chain R₅ containing 1 to 4 carbon atoms, to givethe compound (2) as defined above:

c) conversion of the ester function of the intermediates of generalformula (2) or of methyl 4-bromo-3-methylbenzoate into a tertiaryalcohol function, using at least two equivalents of an organomagnesiumcompound of formula R2-MgX

wherein X is a chlorine or bromine atom

and R2 is a methyl, ethyl, propyl, butyl or isobutyl radical to give thecompound of general formula (3) as defined above:

d) conversion of the aromatic bromide into aryl boronate in the presenceof a solvent, a catalyst, a base and pinacolborane or pinacoldiborane,to give the compound of general formula (I).

In greater detail, the steps of this process may be carried out asfollows:

a. The first step entails performing a bromination in the benzylicposition to give the intermediate (1). This halogenation reaction isdescribed in the literature. Various brominating agents may be used,such as, for example, bromine (K. Smith et al., J. Chem. Soc. Perkin.Trans., I, 2000, 2745), N-bromosuccinimide (P. Liu et al., Synthesis,2001, 2078), sodium bromate (D. Kikuchi et al., J. Org. Chem., 1998,6023) or else 1,3-dibromo-5,5-dimethylhydantoin (H. Jendralla et al.,Liebigs Ann. Chem., 1995, 1253). This reaction is carried out most oftenin chlorinated solvents or in ethers. The brominating agent used withpreference is N-bromosuccinimide at dichloromethane reflux. Preferably,benzoyl peroxide is also used, in a catalytic amount, as a free-radicalreaction initiator. In order to activate the free-radical reaction thereaction mixture is irradiated with a 1000 watt lamp.

This step provides the intermediate (1):

b. The second step entails substituting the bromine introduced in step 1in the benzylic position by an alkyl chain R′1 containing 1 to 4 carbonatoms. In order to promote this substitution reaction the nucleophiliccharacter of the alkyl group R′1 is increased by using an organometallicreagent R1-M in which M is a metal atom such as magnesium, copper orelse zinc. This reaction is documented in the literature (B. H. Lipshutzand S. Sengupta, Organic Reactions, 1992, 41, 135). Preferably, copperin the form of copper iodide is employed in the presence of anorganomagnesium compound R′1-MgX (X═Br, Cl, I) in order to generate anorganocuprate. This reaction may be carried out in ethereal solvents.Preferably the ethereal solvent used is tetrahydrofuran. The reaction iscarried out at low temperature, preferably from −40° C. and 0° C., moreparticularly from −40° C. and −20° C.

This step provides the intermediates of general formula (2), theradicals of which are defined above.

c. The third step entails converting the ester function of theintermediates of general formula (2) or of methyl4-bromo-3-methylbenzoate into a tertiary alcohol function, using atleast two equivalents of an organomagnesium compound of formula R2-MgX,wherein X is a chlorine, bromine or iodine atom and R2 is an alkylradical having 1 to 4 carbon atoms. This reaction is widely described inthe literature. This reaction may be carried out in ethereal solvents.Preferably, the ethereal solvent used is tetrahydrofuran. The reactionis preferably carried out at a temperature of from −20° C. and +20° C.,more particularly from −10° C. and +10° C.

This step provides the intermediates of general formula (3), theradicals of which are defined above.

d. In this fourth step, the aromatic bromide of the intermediates ofgeneral formula (3) may be converted into aryl boronate. This reaction,which is also well described in the literature (a/ M. Murata et al., J.Org. Chem., 1997, 62, 6458; b/ T. Ishiyama et al., J. Org. Chem., 1995,60, 7508), is carried out in solvents such as DMF, tetrahydrofuran, DMSOor else dioxane. The reaction temperatures used are generally close tothe reflux temperatures of the solvents. Generally, use is made of apalladium catalyst, preferablydichloro[1,1′-ferrocenylbis(diphenylphosphane)]palladium(II)dichloromethane or Pd(dppf)Cl₂, a base, preferably potassium acetate ortriethylamine, preferably from 2.5 and 3.5 equivalents, and a borontetraalkoxide, preferably pinacolborane or pinacoldiborane. From 1 and1.5 equivalents of the latter are used, preferably from 1.0 and 1.2equivalents.

The present invention likewise features the use of the disubstitutedderivatives of phenylboronic acid of formula (I) and the compounds (1),(2) and (3) as synthesis intermediates for preparing vitamin Dderivatives.

Preferably, the compounds (I), (1), (2) and (3) according to theinvention are used as intermediates in the synthesis of non-steroidalvitamin D derivatives displaying vitamin D activity.

More preferably, the non-steroidal vitamin D derivatives are compoundsof formula (IV):

in which:

R1 is a hydrogen atom or an alkyl radical having from 1 to 4 carbonatoms,

R2 and R3, which may be identical or different, are each an alkylradical having from 1 to 4 carbon atoms, and

R′₁ is an alkyl radical having from 1 to 4 carbon atoms.

In the preferred embodiment according to the invention, the compoundsaccording to the invention are therefore employed in the synthesisaccording to the scheme indicated in FIG. 4.

According to the invention, the compounds of formula (IV) are preferablyprepared from the compound (12) obtained according to the reactionscheme of FIG. 4. Compound (12) may be obtained from phenylboronic acidderivative compounds of general formula (I) according to the invention.A first reaction is a Suzuki coupling reaction from the derivatives ofgeneral formula (I) according to the invention and an aryl bromide ofgeneral formula (II). The Suzuki reaction product, of general formula(10), is fused with the benzyl bromide (11) in the presence of a basesuch as, for example, potassium carbonate, to give the compounds ofgeneral formula (12). Subsequently, a reaction is employed in accordancewith methods which are well known to one skilled in the art—for example,and without limitation, such as described in WO 03/050067, which allowthe compound (IV) to be obtained from the compound (12).

The present invention therefore features the process for preparingcompounds of formula (IV) from phenylboronic acids of the presentinvention according to the following steps:

a) A Suzuki coupling reaction from the compounds of general formula (I)

in which:

R1 is a hydrogen atom or an alkyl radical having from 1 to 4 carbonatoms,

R2 and R3, which may be identical or different, are each an alkylradical having from 1 to 4 carbon atoms, and

R4 is the —B(OH)₂ radical or the radical of formula:

and an aryl bromide of general formula (II):

in which:

R′₁ is an alkyl radical having from 1 to 4 carbon atoms, to give thecompound of general formula (10):

in which:

R1 is a hydrogen atom or an alkyl radical having from 1 to 4 carbonatoms,

R2 and R3, which may be identical or different, are each an alkylradical having from 1 to 4 carbon atoms, and

R′₁ is an alkyl radical having from 1 to 4 carbon atoms;

b) the Suzuki reaction product, of general formula (10), is fused withthe benzyl bromide (11) in the presence of a base, such as potassiumcarbonate:

c) liberation of the alcohol functions of the compound (11) to give thecompound (IV).

The present invention likewise features the compounds of formula (10),intermediates in the process defined above, of the following formula:

in which:

R1 is a hydrogen atom or an alkyl radical having from 1 to 4 carbonatoms,

R2 and R3, which may be identical or different, are each an alkylradical having from 1 to 4 carbon atoms, and

R′₁ is an alkyl radical having from 1 to 4 carbon atoms; and their usein the synthesis of vitamin D analogues as described above and in FIG.2.

In order to further illustrate the present invention and the advantagesthereof, the following specific examples are given, it being understoodthat same are intended only as illustrative and in nowise limitative. Insaid examples to follow, all parts and percentages are given by weight,unless otherwise indicated.

EXAMPLES Example 1 Step 1: Preparation of Methyl 4-bromo-3-bromomethylbenzoate

In a 6-liter reactor equipped with a condenser, a central mechanicalstirrer and a thermometer, introduce 575 g (2.5 mol) of methyl4-bromo-3-methylbenzoate, 3 liters of methylene chloride, 494 g (2.75mol) of N-bromosuccinimide and 17 g of benzoyl peroxide (0.05 mol; 70%in water). Heat the mixture at reflux under irradiation with a 1000 wattlamp for 10 h. Wash the mixture twice with 1 liter of water, then with 1liter of saturated sodium chloride solution. Evaporate the methylenechloride. Recrystallize the crude product obtained from heptane. Thisgives 596 g of methyl 4-bromo-3-bromomethylbenzoate in the form ofoff-white crystals (Yield=77%)

Melting point: 100-101° C.

¹H NMR (CDCl₃; 400 MHz): 3.94 (s; 3H); 4.64 (s: 2H); 7.68 (d; 1H; Jo=8.3Hz); 7.83 (d×d; 1H; Jo=8.3 Hz and Jm=2.0 Hz); 8.14 (d; 1H; Jm=2.0 Hz)

Step 2: Preparation of Methyl 4-bromo-3-propylbenzoate

In a 6-liter reactor equipped with a condenser, a central mechanicalstirrer, a thermometer and a dropping funnel, introduce under nitrogen141 g (0.46 mol) of methyl 4-bromo-3-bromomethylbenzoate, 4 liters oftetrahydrofuran and 8.9 g (0.045 mol) of copper(I) iodide. Cool themixture to −40° C. using a bath of acetonitrile and dry ice. Add 168 cm³of a 3M solution of ethylmagnesium bromide in diethyl ether and thenallow the reaction temperature to increase to 0° C. After two hours ofreaction hydrolyze the reaction mixture with 1 liter of 2.5M ammoniumchloride solution. Separate the phases and extract the aqueous phasewith 0.7 liter of methylene chloride. Combine the organic phases andevaporate the solvents. Pour heptane onto the product obtained andfilter off the insoluble product which has formed. Evaporate the heptaneand purify the resulting product by chromatography on silica gel(heptane/ethyl acetate=95/5). This gives 51 g of methyl4-bromo-3-propylbenzoate in the form of colorless oil. (Yield=43%)

¹H NMR (CDCl₃; 400 MHz): 1.01 (t; 3H; J₁=7.3 Hz); 1.68 (broad unresolvedpeak; 2H); 2.76 (t; 2H; J₂=7.6 Hz); 3.92 (s; 3H); 7.61 (d; 1H; Jo=8.3Hz); 7.71 (d×d; 1H; Jo=8.3 Hz and Jm=1.8 Hz); 7.89 (d; 1H; Jm=1.8 Hz)

Step 3: Preparation of 3-(4-Bromo-3-propylphenyl)pentan-3-ol

In a 1-liter three-necked round-bottomed flask, equipped with a magneticstirrer, a thermometer and a dropping funnel, introduce under nitrogen47 g (0.18 mol) of methyl 4-bromo-3-propylbenzoate in solution in 250 mlof tetrahydrofuran. Cool the mixture to −5° C. with the aid of a bath ofice and sodium chloride. Add 134 cm³ of a 3 M solution of ethylmagnesiumbromide in diethyl ether, then allow the reaction temperature toincrease without exceeding 5° C. After three hours of reaction,hydrolyze the reaction mixture with 170 cm³ of 2.5 M ammonium chloridesolution. Extend the organic phase with 200 cm³ of ethyl acetate.Separate the phases and extract the aqueous phase with 2×200 cm³ ofmethylene chloride. Combine the organic phases, dry them over sodiumsulfate and evaporate the solvents. This gives 49.8 g of3-(4-bromo-3-propylphenyl)pentan-3-ol in the form of colorless oil.(Yield=96%)

¹H NMR (CDCl₃; 400 MHz): 0.77 (t; 6H; J₂=7.4 Hz); 1.00 (t; 3H; J₁=7.3Hz); 1.68 (broad unresolved peak; 2H); 1.83 (broad unresolved peak; 4H);2.73 (t; 2H; J₂=7.7 Hz); 7.05 (d×d; 1H; Jo=8.3 Hz and Jm=2.2 Hz); 7.24(d; 1H; Jm=2.2 Hz); 7.48 (d; 1H; Jo=8.3 Hz)

Step 4: Synthesis of 441-Ethyl-1-hydroxypropyl)-2-propylphenylboronicacid

In a three-necked flask, introduce under nitrogen 5 g of3-(4-bromo-3-propylphenyl)pentan-3-ol (17.5 mmol) and 50 cm³ oftetrahydrofuran. Cool the mixture to −70° C. and add dropwise 17.5 cm³(43.7 mmol) of a 2.5M solution of n-butyllithium in hexane, over 30minutes. Leave the reaction mixture for approximately 2 h with stirringat −70° C. and then add dropwise 10 cm³ of triisopropylborate (43.7mmol), over 20 minutes. Leave the reaction mixture with stirring for 4h, allowing the temperature to increase to −40° C. Hydrolyse the mixturewith saturated NH₄Cl solution and extract twice with ethyl acetate. Washthe combined organic phases with saturated sodium chloride solution andevaporate the solvents under vacuum. This gives 5.4 g of a colorlessoil, which is chromatographed on silica gel (heptane/ethyl acetate=3/1).This gives 1.92 g of 4-(1-ethyl-1-hydroxypropyl)-2-propylphenylboronicacid in the form of a highly viscous oil. (Yield=44%)

Example 2 Step 1: Preparation of 3-(4-Bromo-3-methylphenyl)pentan-3-ol

In a 4-liter SVL reactor equipped with a magnetic stirrer, a thermometerand a dropping funnel, introduce under nitrogen 198.7 g (0.867 mol) ofmethyl 4-bromo-3-methylbenzoate in solution in 1 liter oftetrahydrofuran. Cool the mixture to −5° C. with the aid of a bath ofice and sodium chloride. Add 636 cm³ of a 3M solution of ethylmagnesiumbromide in diethyl ether, then allow the reaction temperature toincrease to ambient temperature. After four hours of reaction, hydrolyzethe reaction mixture with 2 liters of a 1N hydrochloric acid solution.After decanting and separation, extract the aqueous phase with 0.5 literof ethyl acetate. Wash the combined organic phases with 0.4 liter ofwater (3×). After drying over sodium sulfate, the product obtained afterevaporation of the solvents is purified by chromatography on silica gel(heptane/ethyl acetate=95/5). This gives 150.2 g of3-(4-bromo-3-methylphenyl)pentan-3-ol in the form of a colorless oil(Yield=67%)

¹H NMR (CDCl₃; 400 MHz): 0.79 (t; 6H; J₂=7.4 Hz); 1.63 (s; 1H); 1.83(broad unresolved peak; 4H); 2.42 (s; 3H); 7.05 (d×d; 1H; Jo=8.3 Hz andJm=2.2 Hz); 7.27 (d; 1H; Jm=2.2 Hz); 7.48 (d; 1H; Jo=8.3 Hz)

Step 2: Synthesis of 4-(1-Ethyl-1-hydroxypropyl)-2-methylphenylboronicacid

In a three-necked flask, introduce under nitrogen 5 g of3-(4-bromo-3-methylphenyl)pentan-3-ol (19.4 mmol) and 50 cm³ oftetrahydrofuran. Cool the mixture to −70° C. and add dropwise 23.3 cm³(58 mmol) of a 2.5M solution of n-butyllithium in hexane, over 30minutes. Leave the mixture for approximately 2 h with stirring at −70°C. and then add dropwise 13.5 cm³ of triisopropyl borate (58 mmol), over20 minutes. Leave the mixture with stirring for 3 h, allowing thetemperature to increase to −10° C. Hydrolyse the mixture with saturatedNH₄Cl solution and extract two times with ethyl acetate. Wash thecombined organic phases with saturated sodium chloride solution and drythem over sodium sulfate. Evaporate the solvents under vacuum. Thisgives 5 g of a colorless oil, which is chromatographed on silica gel(heptane/ethyl acetate=9/1) to give4-(1-ethyl-1-hydroxypropyl)-2-methylphenylboronic acid in the form of ahighly viscous oil. (Yield=71%)

¹H NMR (CDCl₃; 400 MHz): 0.78 (t; 3H; J₂=7.4 Hz); 1.86 (broad unresolvedpeak; 4H); 2.86 (s; 3H); 7.31 (m; 3H); 8.22 (d; 1H; Jo=8.3 Hz)

Example 3 Synthesis of3-[3-Propyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]pentan-3-ol

In a three-necked flask, introduce under nitrogen 2 g of3-(4-bromo-3-propylphenyl)pentan-3-ol (7 mmol) and 20 cm³ ofN,N-dimethylformamide. Add 2.06 g (21 mmol) of potassium acetate and1.87 g (7.3 mmol) of bis(pinacol)diborane. Add 0.229 g (0.28 mmol) ofdichloro[1.1′-ferrocenylbis(diphenylphosphane)]palladium(II)dichloromethane [Pd(dppf)Cl₂] and heat the reaction mixture at refluxfor 2 h 30 min. Hydrolyse the mixture and extract it twice with ethylacetate. Wash the combined organic phases with saturated sodium chloridesolution and evaporate the solvents under vacuum. This gives 3.6 g,which is chromatographed on silica gel (heptane/ethyl acetate=8/2). Thisgives 1.55 g of3-[3-propyl-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]pentan-3-olin the form of a highly viscous oil. (Yield=76%)

¹H NMR (CDCl₃; 400 MHz): 0.76 (t; 6H; J₂=7.4 Hz); 0.95 (t; 3H; J₁=7.3Hz); 1.36 (s; 12H); 1.60 (broad unresolved peak; 2H); 1.67 (s; 1H); 1.84(broad unresolved peak; 4H); 2.88 (t; 2H; J₂=7.6 Hz); 7.18 (m; 2H); 7.75(d; 1H; Jo=8.4 Hz)

Each patent, patent application, publication, text and literaturearticle/report cited or indicated herein is hereby expresslyincorporated by reference.

While the invention has been described in terms of various specific andpreferred embodiments, the skilled artisan will appreciate that variousmodifications, substitutions, omissions, and changes may be made withoutdeparting from the spirit thereof. Accordingly, it is intended that thescope of the present invention be limited solely by the scope of thefollowing claims, including equivalents thereof.

1. A non-steroidal vitamin D analogue prepared from a disubstitutedphenylboronic acid compound of the following structural formula (I):

in which: R1 is a hydrogen atom or an alkyl radical having from 1 to 4carbon atoms, R2 and R3, which may be identical or different, are eachan alkyl radical having from 1 to 4 carbon atoms, and R4 is the —B(OH)₂radical or the radical of formula:


2. The non-steroidal vitamin D analogue as defined by claim 1, havingthe structural formula (IV):

in which: R1 is a hydrogen atom or an alkyl radical having from 1 to 4carbon atoms, R2 and R3, which may be identical or different, are eachan alkyl radical having from 1 to 4 carbon atoms, and R′₁ is an alkylradical having from 1 to 4 carbon atoms.
 3. A process for thepreparation of a non-steroidal vitamin D analogue as defined by claim 2,comprising: a) Suzuki coupling a compound having the formula (I):

in which: R1 is a hydrogen atom or an alkyl radical having from 1 to 4carbon atoms, R2 and R3, which may be identical or different, are eachan alkyl radical having from 1 to 4 carbon atoms, and R4 is the —B(OH)₂radical or the radical of formula:

and an aryl bromide having the formula (II):

in which: R′₁ is an alkyl radical having from 1 to 4 carbon atoms, toobtain a compound of formula (10):

b) fusing the Suzuki reaction compound (1) with the benzyl bromide (11)in the presence of a base:

c) liberating the alcohol functions of the compound (11) to obtain thecompound (IV).